GlassScriptPhysician profile
Sable Reynolds
NPI 1902385974
$988.28
in general payments reported to CMS, 2019-2025
10 companies · $920 in 2025
The $920 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $68.75 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $61.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.58 |
| Education | $61.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $293.14 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $256.53 | 2025 | |
| Sight Sciences, INC. | $164.46 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $81.97 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $54.23 | 2024-2025 | Vyzulta, Scoutpro Osmolarity System |
| Dompe US, INC. | $39.27 | 2025 | Oxervate |
| Glaukos Corporation | $31.34 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $24.45 | 2025 | |
| Astellas Pharma US INC | $23.72 | 2025 | Izervay |
| Merz Pharmaceuticals, LLC | $19.17 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sable Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.